Eisai has completed the acquisition of AkaRx for $255 million, in a move which will give it sole worldwide rights to the US firm's thrombocytopenia drug AKR-501.
Eisai has completed the acquisition of AkaRx for $255 million, in a move which will give it sole worldwide rights to the US firm's thrombocytopenia drug AKR-501.
The transaction, first announced last month, was routed through the Japanese firm's US subsidiary, which now wholly owns New Jersey-based...
Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.
The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.
Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.
Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.
